Journal
BLOOD
Volume 130, Issue 23, Pages 2469-2474Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2017-08-784066
Keywords
-
Categories
Funding
- Novartis
- Celgene
- AbbVie
Ask authors/readers for more resources
In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available